Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors

• Published in: Theranostics Vol. 11; no. 9; pp. 4335 - 4350
• Main Authors: Xia, Yiqun, Chen, Jundixia, Yu, Yun, Wu, Fengjiao, Shen, Xin, Qiu, Chenyu, Zhang, Tingting, Hong, Lin, Zheng, Peisen, Shao, Rongrong, Xu, Chenxin, Wu, Fang, Chen, Wei, Xie, Congying, Cui, Ri, Zou, Peng
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher Pty Ltd 01.01.2021; Ivyspring International Publisher
• Subjects: Antibodies; Cancer therapies; Cell growth; Homeostasis; Kinases; Medical prognosis; Metabolism; Oxidative stress; Physiology; Protein synthesis; Research Paper; Signal transduction; Tumors; United States > US; China; mTOR; autophagy; c-Jun N-terminal Kinase; oxidative stress; thioredoxin reductase
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/thno.52077

Cancer is a leading cause of death worldwide. Extensive research over decades has led to the development of therapies that inhibit oncogenic signaling pathways. The mammalian target of rapamycin (mTOR) signaling pathway plays an important role in the development of many cancers. Several mTOR inhibitors are approved for the treatment of cancers. However, the anticancer efficacies of mTOR inhibitor monotherapy are still limited. Western blot was used to detect the expression of indicated molecules. Thioredoxin reductase (TrxR) activity in cells was determined by the endpoint insulin reduction assay. Immunofluorescence staining was used to analyze precise location and expression of target proteins. Nude mice were used for xenograft tumor models. We identified a synergistic lethal interaction of mTOR and TrxR inhibitors and elucidated the underlying molecular mechanisms of this synergism. We demonstrated that mTOR and TrxR inhibitors cooperated to induce cell death by triggering oxidative stress, which led to activation of autophagy, endoplasmic reticulum (ER) stress and c-Jun N-terminal Kinase (JNK) signaling pathway in cancer cells. Remarkably, we found that auranofin (AF) combined with everolimus significantly suppressed tumor growth in HCT116 and SGC-7901 xenograft models with no significant signs of toxicity. Our findings identify a promising therapeutic combination for cancer and has important implications for developing mTOR inhibitor-based combination treatments.